# Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers

> **NCT01827644** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 36 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Afuresertib GC - Fasted State
- **DRUG:** Afuresertib HPMC capsule - Fasted State
- **DRUG:** Afuresertib ECT - Fasted State
- **DRUG:** Afuresertib GC - Fed State
- **DRUG:** Afuresertib HPMC capsule - Fed State
- **DRUG:** Afuresertib ECT - Fed State

## Key facts

- **NCT ID:** NCT01827644
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04-24
- **Primary completion:** 2013-07-12
- **Final completion:** 2013-07-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2017-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01827644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01827644, "Bioavailability and Food Effect of the Original Gelatin Formulation and Two New Formulations of Afuresertib in Normal Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01827644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*